Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: February 14, 2006
Last updated: February 10, 2011
Last verified: February 2011
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2005
  Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)